IMLYGIC® (talimogene laherparepvec) has been genetically modified to replicate within tumors and to produce the immune stimulatory protein granulocyte-macrophage colony-stimulating factor (GM-CSF). When IMLYGIC® is injected into melanoma tumors, it causes lysis of tumor cells followed by release of tumor-derived antigens, which together with virally derived GM-CSF may promote an antitumor immune response. However, the exact mechanism of action is unknown.1
Cancer immunity cycle1,2
![1](https://cdn.imlygichcp.com/cdn/a04d7932-2524-459b-9c5c-8dc78cda0e2a/en/1/20210106t081747z/stage1_localcontrol.png)
![4](https://cdn.imlygichcp.com/cdn/a071d8a8-1ad7-4882-bb04-ef1a68d6ff02/en/1/20210106t081900z/stage4_cancercell.png)
![3](https://cdn.imlygichcp.com/cdn/88d0621e-ff5c-458c-a548-f1af0ed5898d/en/1/20210106t081842z/stage3_maturedendriticcell.png)
![2](https://cdn.imlygichcp.com/cdn/13b8296e-29cb-495e-aa65-692712d51664/en/1/20210106t081807z/stage2_immaturedendriticcell.png)
![Illustration demonstrating the cancer immunity cycle](https://cdn.imlygichcp.com/cdn/30f8bed6-c773-4897-86d9-0aa037a62c2e/en/1/20210106t081707z/imlygic_moa_desktop.jpg)